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Hormonal Management of Advanced Adenocarcinoma of the Prostate
Brian J. Miles, MD*

ince 1941 when Huggins and Hodges (1) demonstrated that
carcinoma of the prostate is a hormonally responsive tumor,
castration or other methods of hormonal ablation have been the
mainstay of deatment for advanced adenocarcinoma ofthe prostate. While orchiectomy remains the gold standard for hormonal
manipulation, alternative treatment methods include diethylstilbestrol (DES), luteinizing hormone-releasing hormone
(LHRH) agonists, and antiandrogens.

S

Orchiectomy/DES
Despite much early hope, numerous clinical trials over the
past four decades have shown that cures and improved survival
with castration and DES are unlikely. The largest series included
studies by Nesbit and Baum (2) in the 1940s and early 1950s and
the Veterans Administration Cooperative Urological Research
Group (VACURG) studies in the 1960s (3).
The cooperative study by Nesbit and Baum (2) in 1950 compared patients with metastatic disease treated by either orchiectomy, DES (1 to 5 mg/day), or a combination of DES and orchiectomy. These 263 patients were followed forfiveyears and
compared to a control group of 231 patients followed between
1925 and 1940 who received no hormonal manipulation. Results
revealed differences in ultimate survival between the hormonally treated group and the control group at five years (17%
versus 6%). Patients treated with orchiectomy or a combination
of DES and orchiectomy had the highest survival rate (20% and
21%, respectively), whereas no difference was observed between the DES and control groups (10% versus 6%). However,
because the control group was a historical series and not concurrent with the study group, it was difficult for the investigators to
conclude, in that preantibiotic era, that the increase in survival
was totally due to hormonal manipulation even though it occurred in late and not early stages of the disease.
In the VACURG study (3) 772 patients were randomly placed
in four treatment groups: placebo, orchiectomy, DES (5 mg/
day), or a combination of orchiectomy and DES. All patients
were followed for five years. Results revealed no statistical difference in survival between the four groups and showed that hormonal manipulation is palliative. The results also indicated that
ultimate survival is apparentiy independent of the timing of hormonal manipulation. Although this study forms the basis for
current clinical use of hormonal manipulation, it was not well
designed. Patients were evaluated based on the original group to
which they were assigned even if their treatment had been
changed because they did not do well with the assigned method
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of treatment. The results, therefore, are extremely difficult to
interpret.
Nonetheless, these results were corroborated in 1982 by
Lepor et al (4) who also used a historical control group to compare ultimate survival to a group of patients with metastatic disease who received standard hormonal therapy. The results
showed no significant difference in ultimate survival between
the two groups.
Based on the preponderance of evidence, the timing of hormonal intervention is not significant in asymptomatic patients
with advanced stage D-2 prostate carcinoma. The only question
remaining concems the significance of early hormonal intervention in patients with stage D-1 disease and questionably minimal
stage D-2 disease (5). In stage D-2 disease palliation is the only
definitive indication for the use of hormonal ablation. Unfortunately, the decision to hormonally ablate an asymptomatic patient with stage D-2 disease is often made without consideration
of quality-of-life issues, such as the individual's sex life. In
these circumstances physicians undoubtedly provide a disservice to these patients.
Orchiectomy remains the gold standard for hormonal manipulation in adenocarcinoma of the prostate. It is definitive, alleviates concerns about patient compliance, has the fewest longterm side effects, and is performed easily with the patient under
local anesthesia. In my practice the majority of men are not troubled by the notion of castration or related body image changes
when they understand all the treatment options and why orchiectomy is necessary in their case.
The main alternative to castration is DES. The VACURG
study (3) proved that 3 mg/day of DES is the safest dose that
provides a persistent and well-defined therapeutic response.
However, the side effects from DES are substantial. The Leuprolide Study Group (6) found a 31% overall severe complication rate in patients on DES and a 27% severe complication rate
in asymptomatic patients with no prior cardiac history. De Voogt
et al (7) and Henriksson and Edhag (8) found similar significant
complication rates with DES. This significant morbidity and
mortality should relegate DES to a secondary role in the management of prostate cancer.
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LHRH Agonists
Despite its significant side effects, DES was the only alternative to castration until this decade when a new class of dmgs
was developed. These LHRH agonists include naferelin, leuprolide, buserelin, and zoladex (6,9). Although only leuprolide
is clinically available, the other dmgs are in various stages of
study. Leuprolide differs from tme LHRH by a change in the 6
position from gly to D-leu and in the 10 position from gly-NHj to
NH, NHCH2CH3. The site of action is the pituitary. The substance is an agonist of gonadotropin releasing hormone, but paradoxically with chronic use is antagonistic to normal LHRH effects and achieves castrate testosterone levels within one month.
The Leuprolide Study Group (6) evaluated 199 patients with new
stage D-2 prostate cancer who received either 3 mg/day of DES
or 1 mg/day of lupron injected subcutaneously. At two years the
progression and survival rates were not significantly different.
The increased cardiovascular morbidity and mortality suffered
by patients on DES was significant.
The principal side effects of LHRH agonists include hot
flashes (up to 90%), fluid retention (2%), and gynecomastia
(3%). Of more than 75 patients at Henry Ford Hospital receiving
leuprolide, none have had any difficulty or shown any reluctance in giving themselves injections. Leuprolide's associated
morbidity and its similar efficacy to DES make it the best alternative to orchiectomy in the management of advanced carcinoma of the prostate.

Antiandrogens
The antiandrogens used for hormonal manipulation consist of
three groups: steroidal, nonsteroidal, and those that inhibit
steroidogenesis (10).
The steroidal agents have both central and peripheral effects:
centrally they decrease the LH levels, and peripherally they
compete with dihydrotestosterone. The three major steroidal
antiandrogens are cyproterone acetate (CPA), megestrol, and
medroxyprogesterone acetate (MPA). CPA, which has generated the most interest, acts by blocking the uptake of dihydrotestosterone by the prostate (7,11). While use of megestrol
is fairly common, in time it becomes ineffective due to a central
escape phenomenon whereby the body overrides the competitive blockade at the pituitary level. The central escape phenomenon is also associated with CPA, but the dmg's strong peripheral effects compensate for this effect. In a phase III trial
comparing CPA, MPA, and DES, Jacobi et al (11) found fiveyear survival rates to be 38% for DES, 32% for CPA, but only
14% for MPA. They also found that at three years the progression rate was 55% for DES, 80% for CPA, and 90% for MPA.
Thus, DES was significandy better than either CPA or MPA in
retarding progression. However, the cardiovascular toxicity was
35% for DES patients and only 10% for CPA patients. Although
antiandrogens have a limited role as primary hormonal ablaters,
if orchiectomy is impossible they are of value because of the significantly lower cardiovascular toxicity compared to DES.
Nonsteroidal antiandrogens have significant peripheral effects. They are especially acceptable as a primary treatment because semm testosterone does not decrease and sexual potency
is usually preserved. However, the primary response rate is only
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Table
Summary of Initial Objective Response Rates*
Treatment
DES/Orchiectomy
Antiandrogens
Cyproterone acetate
Flutamide
Ketoconazole
LHRH analog

Number of
Patients

% Objective
Response

Range

177

83%

80.7-100

51
179
53
191

80%
85%
79%
83%

65.0-100
53.8-100
72.5-100
78.2-86

*From Schuize H. Isaacs JT. Coffery DS. A crifical review of the concept of total androgen ablation in the treatment of prostate cancer In: Murphy GP. ed. Prostate cancer Part
A: Research, endocrine treatment and histopathology. New York: Alan Liss. Inc. 1987:1-19.

60% to 70%, which generally is not prolonged due to incomplete androgen blockade by these medications (12).
The nonsteroidal antiandrogens include flutamide and
RU-23908, a new dmg currently under study. The side effects of
flutamide include severe diarrhea (30%), nausea and vomiting
(30%), and gynecomastia (36%). In clinical use diarrhea is the
primary side effect but usually resolves with dose modification.
RU-23908 has a greater range of toxicity including night blindness, interstitial pneumonitis (which is reversible but occasionally fatal), and alcohol intolerance. Although not yet available
clinically, its associated side effects will limit its use.
The nonsteroidal antiandrogens should not be considered for
primary hormonal ablation. They are currently used only in an
attempt to achieve further palliation in patients whose initial hormone treatment failed. They are also being evaluated in clinical
trials in conjunction with orchiectomy or chemical castration in
order to achieve "total" androgen ablation as a primary
treatment.
The two most important antiandrogens that inhibit steroidogenesis are aminoglutethimide and ketoconazole (13-16).
Ketoconazole impairs the activity of cytochrome P450-dependent enzymes (15) and induces a rapid and sustained decrease in
testicular and adrenal androgen production. Castrate levels of
testosterone are usually achieved within four to eight hours after
an initial dose of400 g. The usual dosage is 200 to 300 mg every
eight hours. The principal side effect is nausea (20%), but hepatotoxicity, which is reversible, can occur although rarely
(1/16,000) (15).
Ketoconazole is a popular treatment option for patients in
whom hormonal manipulation has failed. There is marked subjective response (relief of pain, increased appetite, and improved sense of well being) to treatment in about 50% of patients. Trachtenberg and Pont (14) suggest that this symptomatic
improvement is probably mediated through a combination of
diminishing androgen levels and also by the effects on the
cytochrome P450 system.
A summary comparison of initial objective (complete and
partial) response rates for these various treatment modalities is
presented in the Table.

Total Hormonal Ablation
In 1985 Labrie et al (17) reintroduced the concept of total androgen ablation in the primary management of metastatic or lo-
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cally advanced adenocarcinoma of the prostate. After the initial
work of Huggins and Hodges (1), investigators believed that the
adrenal gland produced more androgen after orchiectomy and
that the increased androgen levels were responsible for reactivation of prostate carcinoma in patients whose hormonal therapy
failed. Recent studies, however, revealed that androgen levels
remain normal in hormonally treated patients (18). Schuize et al
(19) reviewed the results of hypophysectomy and adrenalectomy
for therapeutic response in those patients whose standard hormonal therapy failed. In their summary of the results of seven
studies of bilateral adrenalectomy, the 89 evaluable patients
showed only a 5.6% objective response rate. The 209 padents
from the seven studies of hypophysectomy yielded only a 6.7%
response rate.
These studies indicate that removal of circulating androgens
after failure of hormonal treatment has no significant impact on
the prostate carcinoma. However, this does not negate the hypothesis of Labrie et al (17) that total hormonal ablation at the
dme of initial treatment for metastatic disease will have a more
significant impact than sequential therapy. Animal research has
been performed to test this hypothesis. Studies of rat prostate
cancer by Ellis and Isaacs (20) and by Redding and Schally (21)
showed no significant difference in tumor response to castration
versus castration plus antiandrogens or LHRH treatment versus
LHRH plus antiandrogens. Both studies reported a similar response for castration/LHRH agonists alone or in combination
with antiandrogens. In clinical trials comparing orchiectomy
and CPA, Giuliani et al (22) found one- and two-year survival
rates equal to those found by Murphy et al (23) with DES and
orchiectomy. Schroeder et al (24) reported these same results
when comparing LHRH agonist versus LHRH plus CPA.
These studies strongly indicate that combined initial therapy
for metastatic disease provides no treatment or survival advantage. Early results from a National Cancer Institute sponsored
double-blind intergroup study comparing leuprolide plus
placebo to leuprolide plusflutamidesuggest a slightly increased
disease-free period of approximately 11 weeks for those on combined treatment (personal communication, E.D. Crawford).
However, until survival data are available, this mode of therapy
cannot be considered superior

Conclusions
Orchiectomy remains the gold standard for treating advanced
carcinoma of the prostate. Estrogen therapy is an effective alternative, but its significant cardiovascular side effects should relegate this mode of therapy to a secondary role. LHRH analogs are
excellent altematives to orchiectomy, are well tolerated, and
therefore should be considered as the next best altemative to orchiectomy. No evidence exists to support the concept of total androgen ablation. While antiandrogens are effective modalities of
treatment, they are not superior to standard therapy and thus
should remain secondary to primary hormonal ablation. Their
possibly more important role is to provide symptomatic relief
for patients in whom primary hormonal therapy has failed.
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